Latest News for: sodium channel

Edit

Dravet Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, ...

GetNews 26 Mar 2025
... (IND) application for ETX101, allowing the company to initiate clinical trials for this gene therapy candidate aimed at treating Sodium channel protein type 1 subunit alpha (SCN1A)+ Dravet syndrome.
Edit

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Canoe 13 Mar 2025
The proprietary, non-opioid, NaV 1.7 analgesic program is centered on our lead development candidate, Halneuron®, which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission ... .
  • 1
×